Todos Medical Announce Kingcarlx as Model Ambassador for

Firm additionally retains B2i Digital to reinforce engagement with the investor neighborhood

New York, NY, and Tel Aviv, ISRAEL, Sept. 02, 2022 (GLOBE NEWSWIRE) — through NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a complete medical diagnostics and associated options firm, at present introduced that it has entered right into a model ambassador settlement with Kingcarlx, an American influencer with over 7.4 million followers throughout all platforms (5.8 million on TikTok, 1 million on Instagram and 600,000 on YouTube), for the Firm’s majority-owned 3CL Pharma Ltd. subsidiary’s Tollovid™ 3CL protease inhibitor immune help dietary complement model. Along with Kingcarlx, the Firm is launching the #TolloUp advertising marketing campaign. Kingcarlx shall be targeted on selling the life-style features of the Tollovid model targeted on encouraging followers to make use of the complement every day for added safety within the face of a pandemic world.

“After seeing the latest market analysis research on Tollovid that was revealed in ResearchGate, I’m very excited to have the ability to assist Todos increase the Tollovid model throughout my social media platforms and encourage my followers to #TolloUp earlier than they attend social gatherings the place they might be uncovered to potential infections,” stated Kingcarlx, Tollovid’s new model ambassador. “We’ve been cooped up indoors for the previous two years, so I can relate to the urge to socialize, reconnect, and make new reminiscences. I like hanging out with family and friends, however security at all times comes first and I actually make it a degree to ‘#TolloUp’ earlier than every gathering. Tollovid gives a further layer to assist hold you protected and provide you with extra confidence and safety.”    

Kingcarlx Socials:
Instagram: kingcarlx
TikTok: kingcarlx
YouTube: kingcarlX
Facebook: Kingcarlx
Snapchat: KingcarlX
Twitter: Kingcarlx1
www.kingcarlx.com

Concurrent with this announcement, Todos introduced that it has retained the digital investor relations advertising agency B2i Digital to help the Firm with reaching traders on-line because the Firm seems to increase its shareholder base, primarily concentrating on traders who’re considering firms trying to deal with the numerous Long COVID market alternative.    

“I’m impressed with the Todos administration workforce and their want to handle a wide range of points that adversely have an effect on a majority of Individuals,” stated David Shapiro, President & CEO of B2i Digital, Inc. and Chief Advertising and marketing Officer for the Nationwide Funding Banking Affiliation. “Todos has a diversified portfolio of initiatives together with Tollovid as a pure immune help complement, a sturdy R&D pipeline, COVID testing lab provides and life-saving diagnostic options for the early detection of a wide range of cancers. In contrast to your typical biotech firm, they’ve income from their consumer-marketed complement.  I look ahead to sharing their story with the B2i Digital investor neighborhood.”

“We’re starting to make progress in gaining consciousness within the market for our Tollovid complement and in addition to with the funding neighborhood,” stated Gerald Commissiong, President & CEO of Todos Medical. “Tollovid is a completely well timed model for at present’s challenges. The rising Lengthy COVID disaster we’re in search of to handle with testing, remedy and dietary complement options uniquely positions the Firm. With an estimated 20 million Individuals and over 140 million folks globally affected by Lengthy COVID, it is a world well being disaster that’s severely impacting employee incapacity, employee productiveness and negatively impacting gross home product, as not too long ago acknowledged by the Federal Reserve. It’s tough to think about a extra urgent world well being points than addressing COVID and Lengthy COVID. I imagine {that a} Kingcarlx #TolloUp advertising marketing campaign alongside B2i Digital investor relations platform are essential steps ahead in direction of attaining our aims.”

About Todos Medical Ltd.

Based in Rehovot, Israel with workplaces in New York Metropolis, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic options for the early detection of a wide range of cancers. The Firm’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening know-how utilizing peripheral blood evaluation that examines most cancers’s affect on the immune system, on the lookout for biochemical adjustments in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening exams, TMB-1 and TMB-2 have obtained a CE mark in Europe. Todos not too long ago acquired U.S.-based medical diagnostics firm Provista Diagnostics, Inc. to achieve rights to its Alpharetta, Georgia-based CLIA/CAP licensed lab presently performing PCR COVID testing, Long COVID Panel analyses, and Provista’s proprietary commercial-stage Videssa® breast most cancers blood take a look at. Extra info on Provista is obtainable at www.provistadx.com.

Todos can also be creating blood exams for the early detection of neurodegenerative problems, similar to Alzheimer’s illness. The Lymphocyte Proliferation Take a look at (LymPro Take a look at™) is a diagnostic blood take a look at that determines the power of peripheral blood lymphocytes (PBLs) and monocytes to face up to an exogenous mitogenic stimulation that induces them to enter the cell cycle. It’s believed that sure illnesses, most notably Alzheimer’s illness, are the results of compromised mobile equipment that results in aberrant cell cycle re-entry by neurons, which then results in apoptosis. LymPro is exclusive in using peripheral blood lymphocytes as a surrogate for neuronal cell perform, suggesting a standard relationship between PBLs and neurons within the mind.
Todos shaped the Israeli-based majority-owned three way partnership 3CL Pharma, Ltd with NLC Pharma in March of 2022 to consolidate all the mental property surrounding 3CL protease–based mostly diagnostic testing and growth of 3CL protease botanical and pharmaceutical inhibitors that focus on a basic reproductive mechanism of coronaviruses. 3CL Pharma, by Todos’ model, has commercialized the 3CL protease inhibitor immune help dietary complement Tollovid™ in the USA, is creating the twin mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollovir™, whereas additionally creating the 3CL protease diagnostic TolloTest™.

To buy Tollovid please go to Amazon or www.MyTollovid.com. For extra info, please go to https://www.todosmedical.com/.

Ahead-looking Statements

Sure statements contained on this press launch might represent forward-looking statements. For instance, forward-looking statements are used when discussing our anticipated medical growth packages and medical trials. These forward-looking statements are based mostly solely on present expectations of administration, and are topic to vital dangers and uncertainties that would trigger precise outcomes to vary materially from these described within the forward-looking statements, together with the dangers and uncertainties associated to the progress, timing, value, and outcomes of medical trials and product growth packages; difficulties or delays in acquiring regulatory approval or patent safety for product candidates; competitors from different biotechnology firms; and our means to acquire further funding required to conduct our analysis, growth and commercialization actions. As well as, the next elements, amongst others, may trigger precise outcomes to vary materially from these described within the forward-looking statements: adjustments in know-how and market necessities; delays or obstacles in launching our medical trials; adjustments in laws; incapacity to well timed develop and introduce new applied sciences, merchandise and purposes; lack of validation of our know-how as we progress additional and lack of acceptance of our strategies by the scientific neighborhood; incapacity to retain or entice key workers whose information is important to the event of our merchandise; unexpected scientific difficulties that will develop with our course of; better value of ultimate product than anticipated; lack of market share and strain on pricing ensuing from the competitors; and laboratory outcomes that don’t translate to equally good ends in actual settings, all of which may trigger the precise outcomes or efficiency to vary materially from these contemplated in such forward-looking statements. Besides as in any other case required by legislation, Todos Medical doesn’t undertake any obligation to publicly launch any revisions to those forward-looking statements to replicate occasions or circumstances after the date hereof or to replicate the prevalence of unanticipated occasions. For a extra detailed description of the dangers and uncertainties affecting Todos Medical, please confer with its studies filed sometimes with the U.S. Securities and Change Fee.

Todos Company Contact:
Daniel Hirsch CFO
Todos Medical
917-983-4229 x 104
Dan.h@todosmedical.com

Todos Press Contact:
Kyle Kappmeier
JConnelly
Vice President 973-975-7827
kkapmeier@jconnelly.com